Physician profile
Sue Yu
NPI 1710987672
$5,146.87
in general payments reported to CMS, 2019-2025
39 companies · $827 in 2025
The $827 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $357 · 2021: $409 · 2022: $659 · 2023: $900 · 2024: $1,352 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.86 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Merz Pharmaceuticals, LLC | $493.79 | 2021-2025 | Xeomin |
| Pfizer INC. | $394.49 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $324.50 | 2019-2020 | |
| Argenx US, INC. | $285.10 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $257.69 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $240.13 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $218.40 | 2019-2024 | Ultomiris |
| Radius Health, INC. | $188.95 | 2019-2023 | Tymlos |
| Ucb, INC. | $176.03 | 2024-2025 | Rystiggo |
| Genentech USA, INC. | $153.98 | 2019-2022 | |
| Eisai INC. | $141.66 | 2021-2025 | |
| Lilly USA, LLC | $140.11 | 2019-2025 | Amyvid, Kisunla |
| Lundbeck LLC | $136.33 | 2020-2024 | Vyepti |
| Biogen, INC. | $109.38 | 2019-2024 | Skyclarys |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.